Targeted drugs commonly used for the treatment of pancreatic cancer include epidermal growth factor receptor (EGFR) inhibitors in patients with KRAS WT, poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors in patients with BRCA mutations and neurotrophic tyrosine receptor kinase (NTRK) inhibitors [12, 13]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.